FDA advisers voted Tuesday to recommend a regulatory framework for pathogen-agnostic sequencing, clearing the way for its use as an early-warning diagnostic during U.S. infectious disease outbreaks.
The Microbiology Devices Panel of the Medical Devices Advisory Committee concluded that the technology — known as PAS — has matured sufficiently to serve as a frontline tool when conventional tests fail to identify a pathogen, Healio News reported. The panel’s vote followed a daylong general issues meeting on November 19 where members weighed the method’s potential to detect novel viruses against persistent risks of false results and validation bottlenecks.
“We think that during an outbreak, this kind of sequencing could have great value for early identification of an outbreak,” said Robin Patel, MD, acting chair of the panel. “We’ve evolved to a phase where this kind of testing is distributed now and is available in the field.”
Unlike standard polymerase chain reaction (PCR) assays that hunt for a specific genetic signature, pathogen-agnostic sequencing reads all nucleic acids in a clinical sample — human, bacterial, viral, fungal — without a prior hypothesis.
Joseph Briggs, PhD, deputy director of the FDA’s Division of Microbiology Devices, framed the gap bluntly: “This limitation that traditional molecular tests rely on a priori knowledge of the pathogen sets up an important question: What if we don’t know what we’re looking for? That’s precisely what pathogen-agnostic genomic sequencing technologies are designed to address.”
PAS Supplements Standard Diagnostics Without Replacing Them
- Broader net: PAS does not require doctors to guess which virus or bacterium is making a patient sick; it sequences everything present and matches findings to known genomes.
- Not a replacement: The panel stressed PAS supplements — not replaces — standard diagnostics; positive hits still need confirmation.
Massachusetts Enterovirus Cluster Exposes Current Gaps
A concrete illustration of the stakes emerged from testimony by Shirlee Wohl, PhD, project director at the New England Pathogen Genomics Center of Excellence. In September 2026, a Massachusetts hospital saw a spike in enterovirus infections accompanied by unusual neurological symptoms.
“There are many different enteroviruses,” Wohl told the panel. “And in a state public health setting, we just don’t have the resources to maintain specific assays for every possible enterovirus.”
She added that a validated pathogen-agnostic assay would have yielded actionable data for outbreak management, but none was authorized for clinical use at the time. “There are many examples of scenarios where we in Massachusetts could have really used a validated pathogen-agnostic sequencing to make real public health impact and support outbreak response.”
Validation Paradigm Must Shift, CDC Official Warns
John Barnes, PhD, deputy director of the Office of Advanced Molecular Detection at the Centers for Disease Control and Prevention, explained that current regulatory frameworks assume a test targets a defined organism.
“Our validation paradigms are built around targeted assays and pathogen-agnostic testing really kind of breaks those foundational assumptions,” Barnes said. “It breaks assumptions like positive predictive value when you’re utilizing a test that could truly detect anything in a sample.”
The panel acknowledged that false-positive and false-negative results, long turnaround times, complex bioinformatics outputs, and high per-sample costs remain significant hurdles. Briggs cautioned that these limitations “could delay appropriate response during an outbreak.”
Resource Disparities Threaten Equitable Deployment
While academic medical centers increasingly run metagenomic next-generation sequencing (mNGS) on research protocols, most state and county public health laboratories lack the bioinformatics infrastructure and sustained funding to operate PAS at scale. The FDA executive summary for the meeting said that broader adoption will require federal investment in laboratory instrumentation, cloud-based analysis pipelines, and a workforce trained in genomic epidemiology.
| Challenge | Impact on PAS Deployment | Proposed Mitigation |
|---|---|---|
| Validation standards | No established framework for pan-pathogen assays | FDA to develop new regulatory guidance |
| Bioinformatics capacity | Most public health labs lack compute and expertise | Centralized cloud pipelines; CDC technical assistance |
| Cost per sample | Higher than targeted PCR | Batch processing; reimbursement pathways |
Global Context: Europe and WHO Move in Parallel
FDA to Review Panel Recommendations and Issue Draft Guidance
Pathogen-agnostic sequencing is a population-level surveillance and diagnostic adjunct, not a direct-to-consumer test. Patients should not request PAS for routine illness.
The FDA will now review the panel’s recommendations and issue draft guidance on the regulatory framework, a process the agency indicated would begin in the first quarter of 2027.
References
- FDA. FDA executive summary: General issues meeting on use of pathogen-agnostic sequencing for emergency preparedness and response efforts. Published November 19, 2026.
- FDA. Microbiology Devices Panel of the Medical Devices Advisory Committee meeting. YouTube. Published November 19, 2026.
- Healio News. FDA advisors support pathogen-agnostic sequencing to detect emerging infectious diseases. Published November 20, 2026.